{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["272"],"submitter":["Chiappalupi S"],"funding":["Associazione Italiana per la Ricerca sul Cancro","Fondazione Cassa di Risparmio di Perugia"],"pubmed_abstract":["A novel infectious disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was detected in December 2019 and declared as a global pandemic by the World Health. Approximately 15% of patients with COVID-19 progress to severe pneumonia and eventually develop acute respiratory distress syndrome (ARDS), septic shock and/or multiple organ failure with high morbidity and mortality. Evidence points towards a determinant pathogenic role of members of the renin-angiotensin system (RAS) in mediating the susceptibility, infection, inflammatory response and parenchymal injury in lungs and other organs of COVID-19 patients. The receptor for advanced glycation end-products (RAGE), a member of the immunoglobulin superfamily, has important roles in pulmonary pathological states, including fibrosis, pneumonia and ARDS. RAGE overexpression/hyperactivation is essential to the deleterious effects of RAS in several pathological processes, including hypertension, chronic kidney and cardiovascular diseases, and diabetes, all of which are major comorbidities of SARS-CoV-2 infection. We propose RAGE as an additional molecular target in COVID-19 patients for ameliorating the multi-organ pathology induced by the virus and improving survival, also in the perspective of future infections by other coronaviruses."],"journal":["Life sciences"],"pagination":["119251"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7900755"],"repository":["biostudies-literature"],"pubmed_title":["Targeting RAGE to prevent SARS-CoV-2-mediated multiple organ failure: Hypotheses and perspectives."],"pmcid":["PMC7900755"],"pubmed_authors":["Chiappalupi S","Salvadori L","Riuzzi F","Vukasinovic A","Sorci G","Donato R"],"additional_accession":[]},"is_claimable":false,"name":"Targeting RAGE to prevent SARS-CoV-2-mediated multiple organ failure: Hypotheses and perspectives.","description":"A novel infectious disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was detected in December 2019 and declared as a global pandemic by the World Health. Approximately 15% of patients with COVID-19 progress to severe pneumonia and eventually develop acute respiratory distress syndrome (ARDS), septic shock and/or multiple organ failure with high morbidity and mortality. Evidence points towards a determinant pathogenic role of members of the renin-angiotensin system (RAS) in mediating the susceptibility, infection, inflammatory response and parenchymal injury in lungs and other organs of COVID-19 patients. The receptor for advanced glycation end-products (RAGE), a member of the immunoglobulin superfamily, has important roles in pulmonary pathological states, including fibrosis, pneumonia and ARDS. RAGE overexpression/hyperactivation is essential to the deleterious effects of RAS in several pathological processes, including hypertension, chronic kidney and cardiovascular diseases, and diabetes, all of which are major comorbidities of SARS-CoV-2 infection. We propose RAGE as an additional molecular target in COVID-19 patients for ameliorating the multi-organ pathology induced by the virus and improving survival, also in the perspective of future infections by other coronaviruses.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 May","modification":"2024-12-04T06:48:38.35Z","creation":"2021-02-27T08:16:51Z"},"accession":"S-EPMC7900755","cross_references":{"pubmed":["33636175"],"doi":["10.1016/j.lfs.2021.119251"]}}